Souhaitez-vous accéder aux communiqués récents ?

TORONTO, March 30, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a...

Bagsværd, Denmark, 30 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...

TORONTO, Ontario and NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Bitfarms Ltd. (NASDAQ/TSX: BITF), a North American digital infrastructure and energy company, will participate in a fireside chat at...

- Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418’s rapid, consistent treatment effect and favorable safety profile, with statistically significant and clinically...

MONTRÉAL, 30 mars 2026 (GLOBE NEWSWIRE) -- Bombardier Inc. (« Bombardier ») a annoncé aujourd’hui le report de la date d’expiration de sa sollicitation de consentements précédemment annoncée...

MONTRÉAL, March 30, 2026 (GLOBE NEWSWIRE) -- Bombardier Inc. (“Bombardier”) today announced that it has extended the expiration date of its previously announced consent solicitation (the...

Commercial agreement serves as high-profile third party validation of BullFrog AI’s proprietary capabilities Agreement utilizes BullFrog AI’s end-to-end analytical AI platform to accelerate drug...

KING OF PRUSSIA, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company specializing in molecular glue degraders, today announced that it...

Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 Announced development of a less frequent...

Marvel Biosciences secures $600,000 in non-dilutive funding from Alberta Innovates to support Phase I clinical trials of its autism-focused patented MB-204